The use of SAFEs in different industries or sectors, such as healthcare, fintech, or sustainability, has become increasingly popular as more and more startups look for alternative methods of funding. While the basic structure of SAFEs remains the same across all industries, the unique characteristics of each industry may impact the terms of the SAFE.
Healthcare is one industry where SAFEs have gained significant traction. The healthcare industry is notorious for its long development timelines, high regulatory barriers, and significant upfront costs. This means that startups in the healthcare space often require a lot of funding before they can reach profitability.
SAFEs are particularly well-suited to healthcare startups because they allow these companies to raise capital quickly and easily without the need for complex valuations or lengthy negotiations. On the other hand, a standard SAFE does not include sufficient representations and warranties to reflect the startup regulatory situation in relation to the FDA or other relevant authorities. The lack of such representations create a situation where key elements of the risks involved in investing in the startup are not explicitly disclosed.
Example of possible representations and warrants that may be added or rewarded to better reflect the startup legal situation (taken from the NVCA model documents):
- FDA Approvals. The Company possesses all permits, licenses, registrations, certificates, authorizations, orders and approvals from the appropriate federal, state or foreign regulatory authorities necessary to conduct its business, including all such permits, licenses, registrations, certificates, authorizations, orders and approvals required by the U.S. Food and Drug Administration (“FDA”) or any other federal, state or foreign agencies or bodies engaged in the regulation of drugs, pharmaceuticals, medical devices or biohazardous materials.The Company has not received any notice of proceedings relating to the suspension, modification, revocation or cancellation of any such permit, license, registration, certificate, authorization, order or approval. Neither the Company nor, to the Company’s knowledge, any officer, employee or agent of the Company has been convicted of any crime or engaged in any conduct that has previously caused or would reasonably be expected to result in (A) disqualification or debarment by the FDA under 21 U.S.C. Sections 335(a) or (b), or any similar law, rule or regulation of any other Governmental Entities, (B) debarment, suspension, or exclusion under any Federal Healthcare Programs or by the General Services Administration, or (C) exclusion under 42 U.S.C. Section 1320a-7 or any similar law, rule or regulation of any Governmental Entities. Neither the Company nor any of its officers, employees, or to the Knowledge of seller, any of its contractors or agents is the subject of any pending or threatened investigation by FDA pursuant to its “Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities” policy as stated at 56 Fed. Reg. 46191 (September 10, 1991) (the “FDA Application Integrity Policy”) and any amendments thereto, or by any other similar Governmental Entity pursuant to any similar policy. Neither the Company nor any of its officers, employees, contractors, and agents has committed any act, made any statement or failed to make any statement that would reasonably be expected to provide a basis for FDA to invoke the FDA Application Integrity Policy or for any similar governmental entity to invoke a similar policy. Neither the Company nor any of its officers, employees, or to the Company’s Knowledge, any of its contractors or agents has made any materially false statements on, or material omissions from, any notifications, applications, approvals, reports and other submissions to FDA or any similar governmental entity.
- FDA Regulation. The Company is and has been in compliance with all applicable laws administered or issued by the U.S. Food and Drug Administration (“FDA”) or any similar governmental entity, including the Federal Food, Drug, and Cosmetic Act and all other Laws regarding developing, testing, manufacturing, marketing, distributing or promoting the products of the Company, or complaint handling or adverse event reporting.
In the fintech space, SAFEs have become a popular way for startups to raise capital as they look to disrupt traditional financial services. Fintech startups often have unique business models that can be difficult to value, and SAFEs provide a way for investors to participate in these startups’ growth without the need for a traditional priced round. Here is well the addition of representations and warranties which relate to existence and compliance with licenses the startup may need, could be important in presenting the startup situation. Here is an example:
Regulatory Permits. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports, except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (“Material Permits”), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification of any Material Permit.
In each of these industries, the unique characteristics of the sector can impact the terms of the SAFE. For example, in the healthcare industry, investors may be more willing to accept a lower valuation cap because of the high upfront costs and long development timelines associated with healthcare startups. In the fintech space, investors may be willing to accept a higher valuation cap because of the potential for rapid growth and disruption in the traditional financial services industry.
Overall, the use of SAFEs in different industries and sectors has provided startups with a flexible and efficient way to raise capital. While the basic structure of SAFEs remains the same, the unique characteristics of each industry can impact the terms of the SAFE.
By understanding these differences, both startups and investors can make more informed decisions about the type of SAFEs that are most appropriate for their particular industry or sector.
DISCLAIMER
This content is brought to you for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained on this website constitutes a solicitation, recommendation, endorsement, or offer by any person or any third party service provider to buy or sell any securities or other financial instruments in this or in in any other jurisdiction in which such solicitation or offer would be unlawful under the securities laws of such jurisdiction.
THIS ARTICLE IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND DO NOT CONSTITUTE LEGAL ADVICE. THIS ARTICLE IS PROVIDED WITHOUT ANY WARRANTY, EXPRESS OR IMPLIED, INCLUDING AS TO ITS LEGAL EFFECT AND COMPLETENESS. THE INFORMATION SHOULD BE USED AS A GUIDE AND MODIFIED TO MEET YOUR OWN INDIVIDUAL NEEDS AND THE LAWS OF YOUR STATE, BY INDEPENDENT COUNSEL YOU RETAIN. YOUR USE OF ANY INFORMATION CONTAINED IN THIS ARTICLE, IS AT YOUR OWN RISK. WE, OUR EMPLOYEES, CONTRACTORS, OR ATTORNEYS WHO PARTICIPATED IN PROVIDING THE INFORMATION CONTAINED HEREIN, EXPRESSLY DISCLAIM ANY WARRANTY, AND BY DOWNLOADING OR USING OR RELYING ON THIS ARTICLE; NO ATTORNEY-CLIENT RELATIONSHIPS ARE CREATED. DO NOT USE THIS ARTICLE WITHOUT AN INDEPENDENT LAWYER YOU HAVE SPECIFICALLY RETAINED FOR SUCH PURPOSE.
© 2023 Yair Udi – Law Offices. All rights reserved
